Science

Fabio Ynoe de Moraes: Precision RT + Targeted Therapy in Inoperable Stage I–III NSCLC – The Next Frontier?

Fabio Ynoe de Moraes/scri.queensu.ca

Aug 7, 2025, 14:12

Fabio Ynoe de Moraes: Precision RT + Targeted Therapy in Inoperable Stage I–III NSCLC – The Next Frontier?

Fabio Ynoe de Moraes, Associate Professor at Queen’s University, shared a post on LinkedIn:

“Precision RT + Targeted Therapy in Inoperable Stage I–III NSCLC: The Next Frontier?

A new IASLC ART review highlights a clear biological rationale and emerging trial evidence for combining targeted therapies (e.g., EGFR/ALK TKIs) with radiotherapy in inoperable early‑stage and locally advanced NSCLC.

The LAURA phase III trial is a practice‑changer: adjuvant osimertinib after chemoradiotherapy extended median PFS to 39.1 months vs. 5.6 months.

Key clinical practice implications:

Test early: Molecular profiling in stage I–III NSCLC should be standard before MDT discussion.
Select smartly: Targeted therapy benefits are mutation‑specific—most data exist for EGFR, with ALK, RET, and others under study.
Sequence strategically: Neoadjuvant, concurrent, and adjuvant approaches have distinct biological rationales and toxicity profiles.
Monitor safety: Concurrent TKI + RT may increase pneumonitis risk—timing matters.

Plan for the CNS: Agents with strong brain penetration reduce intracranial relapse risk.

Methodology: This was a structured narrative review across PubMed, EMBASE, and ClinicalTrials.gov, with trial tables summarizing efficacy, toxicity, and design quality—critical for translating findings into real‑world practice.

Final message: Early molecular testing, thoughtful patient selection, and trial‑informed sequencing can help bring precision medicine into the curative‑intent radiotherapy setting for NSCLC.”

Title: Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee

Authors: Sarah Bowen Jones, Clara Chan, Andrea Filippi, Ken Harada, Alexander Louie, Colin Lindsay, Ernest Nadal, Pablo Munoz Schuffenegger, David Woolf, Corinne Faivre-Finn

You can read the Full Article in the Journal of Thoracic Oncology.

Fabio Ynoe de Moraes: Precision RT + Targeted Therapy in Inoperable Stage I–III NSCLC - The Next Frontier?

More posts featuring Fabio Ynoe de Moraes on OncoDaily.

Alexander Louie ALK Andrea Filippi cancer Clara Chan Colin Lindsay Corinne Faivre-Finn David Woolf EGFR Ernest Nadal Fabio Ynoe de Moraes IASLC ART Ken Harada LAURA trial NSCLC OncoDaily Oncology Pablo Munoz Schuffenegger Precision RT Sarah Bowen Jones targeted therapy

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...